AI-Powered Drug Discovery
On the glorious day of September 28, 1928, Alexander Fleming revolutionised the field of medicine by discovering penicillin, the first antibiotic to kill bacteria. However, it took more than a decade to be prescribed as a drug in the US. Even today, it takes an average of 10–15 years to develop one medicine or drug from its discovery and get it approved (DiMasi, J. A., et al, 2009). We can say that the process of drug discovery has always been a laborious and costly one, which often takes years and requires substantial financial resources to bring a single drug to market. However, recent advancements in artificial intelligence (AI) have paved the way for a revolution in drug discovery. AI-powered drug discovery is transforming the pharmaceutical industry by accelerating the identification of potential drug candidates, streamlining the research and development process, and ultimately improving patient outcomes.
Principles of AI powered drug discovery
Machine learning and Deep learning: AI-powered drug discovery depends on machine learning and deep learning, data integration, and predictive modelling. Machine learning and deep learning algorithms form the core of AI-powered drug discovery. These algorithms analyse vast datasets containing biological and chemical information to identify potential drug candidates and predict their efficacy. Machine learning models can uncover complex patterns and relationships that may not be apparent through traditional methods, leading to more informed decision-making in drug development.
Data integration: Drug discovery requires the integration of diverse data sources, including genomics, proteomics, chemical databases, and clinical trial data. AI systems are capable of aggregating and analysing this disparate information, enabling researchers to identify novel targets and compounds for drug development.
Predictive modelling: AI algorithms can create predictive models that simulate the behaviour of potential drugs within the human body. This modelling allows researchers to anticipate how drugs will interact with biological systems, predict their safety profiles, and optimise dosing regimens.
Traditional drug discovery vs Computer aided drug discovery (CADD)
Let's explore the distinctions between traditional drug discovery and development and computer-aided drug discovery. As we know, the drug development steps include the discovery and development of drugs based on research or random trials of compounds, then preclinical research of potential drug (pharmacokinetics and pharmacodynamics of the drug), clinical trials, and FDA review. In the conventional method, scientists perform experiments to develop a potential drug, which is a time-consuming process with a greater risk of failure due to human errors. However, in computer-aided drug discovery (CADD), the shortcomings of the traditional drug discovery approach can be avoided. "CADD employs computational chemistry and molecular modelling to discover, create, and develop potential therapeutic compounds with minimal errors, consequently reducing the time and financial resources required. While drugs designed through CADD must still undergo preclinical studies, clinical trials, and FDA review, Computer-aided drug design is cost-effective, fast, accurate, and cost-saving. It also provides a better understanding of the mechanism of action of the drug.
Applications of AI-Powered drug discovery
Applications of AI-powered drug discovery include target identification and validation, compound screening, drug design, and clinical trial optimization.
Target identification and validation: AI helps identify and validate potential drug targets by analysing biological data and identifying proteins, genes, or other molecules that play a key role in disease processes. This step is crucial in the early stages of drug discovery.
Drug repurposing: It can also identify existing drugs that may be repurposed for new therapeutic purposes. By analysing drug databases and biological data, AI systems can pinpoint drugs with potential efficacy against different diseases, saving time and resources.
Compound screening: AI accelerates the screening of chemical compounds by predicting their binding affinity to specific target molecules. This reduces the need for extensive laboratory testing, enabling researchers to focus on the most promising candidates.
Drug design: AI-driven drug design involves the generation of novel drug candidates through computational techniques. AI models can generate molecular structures that optimise drug potency and minimise side effects.
Clinical trial optimization: AI can optimise clinical trial design by identifying patient populations most likely to respond to a particular drug and predicting potential adverse events. This improves the efficiency of drug development and increases the likelihood of successful trials.
Success Stories in AI-Powered Drug Discovery
BenevolentAI, Exscientia, Atomwise, and AlphaFold by DeepMind are some of the AI-driven tools that aid in drug discovery.
DeepMind's AlphaFold: DeepMind's AlphaFold is an AI system that uses deep learning to predict the 3D structures of proteins with remarkable accuracy. This breakthrough has profound implications for drug discovery, as understanding protein structures is crucial for designing drugs that target specific proteins involved in diseases.
Fig2: Prediction of 3D protein structure by DeepMind’s AlphaFold
Atomwise: Atomwise is a company that employs AI for drug discovery by simulating the binding of small molecules to proteins. Their platform has identified potential drug candidates for a range of diseases, including Ebola and multiple sclerosis.
BenevolentAI: BenevolentAI uses AI to mine vast biomedical datasets and discover new drug targets. They have made significant strides in finding potential treatments for amyotrophic lateral sclerosis (ALS) and Parkinson's disease.
The Future of AI-Powered Drug Discovery
AI has the potential to guide an era of personalised medicine where drugs are tailored to individual patients based on their genetic and molecular profiles. AI can expedite the discovery of treatments for rare and neglected diseases that may not be economically viable for traditional drug development. AI can also improve drug safety by predicting adverse events before they occur and helping pharmaceutical companies develop safer drugs. This can lead to fewer drug recalls and increased patient safety. Complex diseases like cancer and neurodegenerative disorders often involve multiple genes and pathways. AI can decipher these complexities and identify novel drug combinations that target multiple aspects of the disease.
Conclusion
There are a few challenges that CADD may face. AI in drug discovery depends vastly on the availability and quality of data. Biomedical data can be messy, incomplete, or biased, which can lead to inaccurate predictions. Efforts are ongoing to improve data collection and curation. Validating AI-generated drug candidates and predictions is crucial to ensuring their reliability. The reproducibility of results across different datasets and laboratories is a challenge that researchers must address. AI models, particularly deep learning models, are often considered "black boxes" because it can be challenging to understand how they arrive at their predictions. This lack of interpretability can hinder regulatory approval and trust in the results. But by addressing the challenges and harnessing the power of AI, we can expect a brighter future for drug discovery and improved healthcare for all.
MD: The article talks about how AI is transforming drug discovery by accelerating candidate identification, enhancing research processes, and improving patient outcomes. Learn about AI principles, applications, and success stories in the pharmaceutical industry. Discover the potential of AI in personalized medicine and the challenges it faces.
A story of Glucose, Insulin and Cancer Cell Growth
Basics of Behavioural Genetics
Benign vs. Malignant Tumors: Understanding the Critical Distinction